Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research
Former TAP Partner
DUBLIN, Nov. 3, 2022 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that abstracts will be presented at the American Society of Hematology (ASH) Annual Meeting from December 10-13, 2022. Research findings to be presented include data from company-sponsored, investigator-sponsored and collaborative trials for Vyxeos® (daunorubicin and cytarabine).
Vyxeos Presentations
|
Presentation Title |
Author |
Presentation Details |
|
V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia by FLT3 Mutation Type |
McCloskey J, et al. |
Type: Poster Session: 615 Date: Saturday, December 10, 2022, 5:30 PM-7:30 PM Abstract number: 1436 |
|
Lower-Intensity CPX-351 + Venetoclax for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Post Hoc Analysis by Disease Risk Subgroups |
Lin, T.L. et al. |
Type: Poster Session: 615 Date: Saturday, December 10, 2022, 5:30 PM-7:30 PM Abstract number: 1423 |
|
CREST-UK: CPX-351 Real-World Effectiveness and Safety Study for the Treatment of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes in the UK |
Mehta, P. et al. |
Type: Poster Session: 615 Date: Sunday, December 11, 2022, 6:00 PM-8:00 PM Abstract number: 2739 |
|
Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) |
Senapati, J. et al. |
Type: Poster Session: 616 Date: Monday, December 12, 2022, 6:00 PM-8:00 PM Abstract number: 4078 |
|
Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial |
Othman, J. et. al |
Type: Oral Presentation Session: 617 Date: Sunday, December 11, 2022: 10:30 AM Abstract number: 431 |
|
Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients |
Heuser, M. et al. |
Type: Poster Session: 615 Date: Sunday, December 11, 2022, 6:00 PM-8:00 PM Abstract number: 2704 |
|
Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization |
Keiffer, G. et al. |
Type: Poster Session: 615 Date: Saturday, December 10, 2022, 5:30 PM-7:30 PM Abstract number: 1439 |
|
Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351 |
Le Bris, Y. et al. |
Type: Poster Session: 637 Date: Monday, December 12, 2022, 6:00 PM-8:00 PM Abstract number: 4413 |